RACHEL SIMMONS: Open Payments
NPI 1962753616 · BAKER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,899 in 32 payments from 9 companies in 2025. Trend: 2023 $788 · 2024 $586 · 2025 $6,899
Speaker / faculty: $6,250Food & beverage: $405Travel & lodging: $244
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $6,686 |
| AstraZeneca Pharmaceuticals LP | 4 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| TOLMAR, INC. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $16 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: VRAYLAR, BREZTRI, QULIPTA, CAPLYTA, JATENZO, Kerendia, XIFAXAN, IBSRELA.
Industry payments across LA — which companies pay providers there.
